Rhythm Pharmaceuticals, Inc. (RYTM) Market Cap & Valuation Ratios
Rhythm Pharmaceuticals, Inc. (RYTM) has a market cap of $6.1B and a price-to-sales ratio of 25.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RYTMRhythm Pharmaceuticals, Inc.Follow RYTM — free
—
Price chart with a free account
- Market cap
- 6.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| RYTM | 6.1 | — | 24.7 | — | -1.7% | +54% | -84% | -140% |
| IONS | 7.1 | — | 7.3 | — | -7.9% | -7% | -68% | -42% |
| PRAX | 7.1 | — | — | — | -4.3% | — | — | -68% |
| IOVA | 6.4 | — | 18.7 | — | -4.6% | +35% | -93% | -51% |
| LGND | 6.1 | 32.3 | 20.0 | 45.6 | 2.2% | +55% | 33% | 9% |
| IMVT | 5.9 | — | — | — | -6.9% | — | — | — |
| MANE | 5.8 | — | — | — | -1.4% | — | — | -21% |
| KOD | 5.5 | — | — | — | -2.9% | — | — | — |
| CGON | 5.5 | — | 713.7 | — | -3.3% | +1030% | — | -25% |
| COGT | 5.4 | — | 615.8 | — | -5.7% | — | — | -120% |
| ORKA | 5.3 | — | — | — | -1.9% | — | — | -28% |
| Median of these 10 | 32.3 | 20.0 | 45.6 | -3.8% | +45% | -68% | -35% |
; EV/Sales 24.7 vs. 20.0.
Growth vs. price
each dot a company · hover or tap for valuesRhythm Pharmaceuticals, Inc. — questions
- What is Rhythm Pharmaceuticals, Inc.'s market cap?
- $6.1B.
- What is Rhythm Pharmaceuticals, Inc.'s price-to-sales ratio?
- 25.6.
Every figure on this page comes from Rhythm Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.